AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17330512 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocotrienol-rich vitamin E (TRE) 80 mg
Number of subjects: 36
Study 17330512 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocotrienol-rich vitamin E (TRE) 160 mg
Number of subjects: 36
Study 17330512 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocotrienol-rich vitamin E (TRE) 320 mg
Number of subjects: 36
Study 17330512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 12956745 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced sputum T cell stimulation
Number of subjects: 32
Study 12956745 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-asthmatics)
Number of subjects: 32
Study 11112128 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (200 microg, twice a day for 7 or 8 days)
Number of subjects: 16
Study 9169965 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (2, 6, 10, or 16 mg/day)
Number of subjects: 523
Study 9169965 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (6 mg/day)
Number of subjects: 523
Study 9169965 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (16 mg/day)
Number of subjects: 523
Study 9169965 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (20 mg/day)
Number of subjects: 523
Study 9169965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 523
Study 8230337 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube thoracostomy (n = 19)
Number of subjects: 40
Study 8230337 — intervention group
Group type: COMPARATOR
Intervention: Observation (n = 21)
Number of subjects: 40
Study 3782046 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (flexible dose)
Number of subjects: 22
Study 31740427 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel treatment (specifics not provided)
Number of subjects: 0
Study 31740427 — intervention group
Group type: COMPARATOR
Intervention: Historical control data
Number of subjects: 0
Study 29439973 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-2969b (60 mg, 200 mg, 400 mg)
Number of subjects: 24
Study 29439973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 27400997 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin D weekly for 16 weeks
Number of subjects: 80
Study 27400997 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 80
Study 24557009 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 55
Study 24557009 — intervention group
Group type: COMPARATOR
Intervention: Time/attention control
Number of subjects: 55
Study 21993377 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered intraperitoneal bemiparin (BM)
Number of subjects: 0
Study 21993377 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 20534324 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese individuals
Number of subjects: 180
Study 19033019 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionuclide angiography (RNA)
Number of subjects: 2521
Study 19033019 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 2521
Study 19033019 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast angiography
Number of subjects: 2521
Study 19033019 — intervention group
Group type: COMPARATOR
Intervention: RNA vs Echocardiography
Number of subjects: 2521
Study 19033019 — intervention group
Group type: COMPARATOR
Intervention: RNA vs Contrast Angiography
Number of subjects: 2521
Study 19033019 — intervention group
Group type: COMPARATOR
Intervention: Echocardiography vs Contrast Angiography
Number of subjects: 2521
Study 17081396 — intervention group
Group type: EXPERIMENTAL
Intervention: TMLR/OPCAB (n = 40)
Number of subjects: 80
Study 17081396 — intervention group
Group type: COMPARATOR
Intervention: OPCAB (n = 40)
Number of subjects: 80
Study 14980919 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 124
Study 14980919 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (40 mg)
Number of subjects: 124
Study 14980919 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental 0.25 mg/kg
Number of subjects: 124
Study 14980919 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental 0.5 mg/kg
Number of subjects: 124
Study 11710599 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy (HFX RT) alone
Number of subjects: 130
Study 11710599 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy (HFX RT) with concurrent low-dose, daily cisplatin (CDDP)
Number of subjects: 130
Study 9329791 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperlipidemia (DM‐HTG and DM‐HLP)
Number of subjects: 0
Study 9329791 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperlipidemia (DM‐HLP)
Number of subjects: 0
Study 9329791 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls or diabetics with normal serum lipids
Number of subjects: 0
Study 8201562 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltaren Ophthalmic)
Number of subjects: 148
Study 8201562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 8201562 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 148
Study 3302004 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg at night
Number of subjects: 44
Study 3302004 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg at night
Number of subjects: 44
Study 3302004 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg at night (open evaluation)
Number of subjects: 44
Study 3302004 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 44
Study 28986942 — intervention group
Group type: EXPERIMENTAL
Intervention: Aroma-massage with acupressure + exercise
Number of subjects: 60
Study 28986942 — intervention group
Group type: EXPERIMENTAL
Intervention: Aroma-massage with acupressure + cognitive training
Number of subjects: 60
Study 28986942 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training + exercise
Number of subjects: 60
Study 27484695 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue perfusion-guided treatment strategy based on capillary refill time, peripheral temperature, arterial lactate concentrations, and lower MAP levels.
Number of subjects: 200
Study 27484695 — intervention group
Group type: COMPARATOR
Intervention: Macrocirculation target-guided standard care.
Number of subjects: 200
Study 27484695 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue perfusion-guided treatment strategy
Number of subjects: 200
Study 23677960 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmar fixed-angle plate fixation
Number of subjects: 40
Study 23677960 — intervention group
Group type: COMPARATOR
Intervention: K-wire fixation
Number of subjects: 40
Study 23751736 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 39
Study 20925617 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy followed by ovarian stimulation and timed intercourse for six cycles
Number of subjects: 512
Study 20925617 — intervention group
Group type: COMPARATOR
Intervention: Ovarian stimulation and timed intercourse for six cycles
Number of subjects: 512
Study 17988905 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised 3% polidocanol foam
Number of subjects: 106
Study 17988905 — intervention group
Group type: COMPARATOR
Intervention: 3% liquid polidocanol
Number of subjects: 106
Study 16344278 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 97
Study 16344278 — intervention group
Group type: COMPARATOR
Intervention: Mayo regimen (i.v. 5-FU/LV)
Number of subjects: 97
Study 16344278 — intervention group
Group type: COMPARATOR
Intervention: OPdG (i.v. 5-FU/LV)
Number of subjects: 97
Study 14594790 — intervention group
Group type: COMPARATOR
Intervention: 0 mg Fe (control)
Number of subjects: 11
Study 14594790 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Fe
Number of subjects: 11
Study 14594790 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg Fe
Number of subjects: 11
Study 10916520 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased skim or 1% milk intake by 3 cups per day (n = 101)
Number of subjects: 204
Study 10916520 — intervention group
Group type: COMPARATOR
Intervention: Maintain usual diet (n = 103)
Number of subjects: 204
Study 8727861 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipstick screening for hematuria
Number of subjects: 659
Study 8727861 — intervention group
Group type: COMPARATOR
Intervention: No dipstick screening for hematuria (hematuria-negative)
Number of subjects: 659
Study 1550148 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 in a controlled-release vaginal pessary
Number of subjects: 81
Study 1550148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 3895595 — intervention group
Group type: EXPERIMENTAL
Intervention: MaxEpa (fish oil concentrate)
Number of subjects: 11
Study 3895595 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 11
Study 29728858 — intervention group
Group type: EXPERIMENTAL
Intervention: ceramide complex cream
Number of subjects: 39
Study 29728858 — intervention group
Group type: COMPARATOR
Intervention: placebo cream
Number of subjects: 39
Study 26814686 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan (endothelin antagonist)
Number of subjects: 52
Study 26814686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 23713836 — intervention group
Group type: EXPERIMENTAL
Intervention: context-focused therapy
Number of subjects: 41
Study 22226683 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme hypofractionated radiotherapy (35 Gy in five fractions)
Number of subjects: 53
Study 22226683 — intervention group
Group type: EXPERIMENTAL
Intervention: First two fractions of treatment
Number of subjects: 53
Study 20038728 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (12 weeks)
Number of subjects: 50
Study 20038728 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine (12 weeks)
Number of subjects: 50
Study 19100066 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretics (n = 200)
Number of subjects: 1080
Study 19100066 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (n = 324)
Number of subjects: 1080
Study 19100066 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan + Hydrochlorothiazide (Hyzaar, n = 476)
Number of subjects: 1080
Study 15638942 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician's assessment of cough quality (wet/dry)
Number of subjects: 106
Study 15638942 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician's cough assessment compared to bronchoscopy (bronchoscopic secretion grade 4)
Number of subjects: 106
Study 15638942 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC curve for cough quality related to airway secretions
Number of subjects: 106
Study 15638942 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-observer agreement for wet/dry cough
Number of subjects: 106
Study 15638942 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-clinician agreement for wet/dry cough
Number of subjects: 106
Study 15638942 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-rater agreement for bronchoscopic secretion grades
Number of subjects: 106
Study 15638942 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity for brassy cough (for tracheomalacia)
Number of subjects: 106
Study 15638942 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra and inter-observer clinician agreement for brassy cough
Number of subjects: 106
Study 12902410 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc-tetrofosmin SPECT
Number of subjects: 83
Study 12902410 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 83
Study 10507245 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate 50 mg tablet administered in fasting condition
Number of subjects: 0
Study 10507245 — intervention group
Group type: COMPARATOR
Intervention: Metrifonate 50 mg tablet administered after high-fat/high-calorie breakfast
Number of subjects: 0
Study 10507245 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate 80 mg tablet administered at 8:00 a.m. after overnight fasting
Number of subjects: 0
Study 10507245 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate 80 mg tablet administered at 7:00 p.m. (7 h after lunch)
Number of subjects: 0
Study 10507245 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate 80 mg tablet administered at 10:00 p.m. (4 h after dinner)
Number of subjects: 0
Study 10507245 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate administration (all studies)
Number of subjects: 0
Study 10507245 — intervention group
Group type: COMPARATOR
Intervention: Metrifonate administration with food
Number of subjects: 0
Study 10507245 — intervention group
Group type: COMPARATOR
Intervention: Metrifonate administration at different times (morning vs evening)
Number of subjects: 0
Study 7856894 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 20
Study 7856894 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 20
Study 7856894 — intervention group
Group type: EXPERIMENTAL
Intervention: Both anesthetics
Number of subjects: 20
Study 2026286 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aid with most midfrequency amplification
Number of subjects: 13
Study 2026286 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aid with intermediate midfrequency gain
Number of subjects: 13
Study 2026286 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech Intelligibility Rating Test (SIR) results
Number of subjects: 13
Study 6798601 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (10 mg/70 kg body weight)
Number of subjects: 20
Study 6798601 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 20
Study 31514108 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology taping with exercise
Number of subjects: 34
Study 31514108 — intervention group
Group type: COMPARATOR
Intervention: Exercise without kinesiology taping
Number of subjects: 34
Study 27966722 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut oil (CO) 22.25 g
Number of subjects: 16
Study 27966722 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut oleogel (CG) 25 g
Number of subjects: 16
Study 27966722 — intervention group
Group type: COMPARATOR
Intervention: Control (orange juice and rice porridge)
Number of subjects: 16
Study 26421692 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR) training for 8 weeks (approximately 20 hours)
Number of subjects: 56
Study 26421692 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) for 8 weeks
Number of subjects: 56
Study 23389113 — intervention group
Group type: EXPERIMENTAL
Intervention: Diurnal carbohydrate/nocturnal protein (DCNP)
Number of subjects: 58
Study 23389113 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal carbohydrate/diurnal protein (NCDP)
Number of subjects: 58
Study 23389113 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CT)
Number of subjects: 58
Study 22317004 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety device plus workshop
Number of subjects: 796
Study 22317004 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop only
Number of subjects: 796
Study 22317004 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 796
Study 19241773 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac 0.09% twice daily
Number of subjects: 212
Study 19241773 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 0.4% four times daily
Number of subjects: 212
Study 17143108 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate
Number of subjects: 5
Study 15341981 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (40 mg/m2 weekly infusion)
Number of subjects: 57
Study 15341981 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (40 mg/m2 weekly bolus i.v. injection)
Number of subjects: 57
Study 15341981 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival and time to progression
Number of subjects: 57
Study 11599317 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 45
Study 11599317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 45
Study 11599317 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (Control)
Number of subjects: 45
Study 10919587 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (Lomir)
Number of subjects: 210
Study 10919587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 8795768 — intervention group
Group type: EXPERIMENTAL
Intervention: Slit-lamp biomicroscopy with Volk 60 D lens
Number of subjects: 25
Study 8795768 — intervention group
Group type: EXPERIMENTAL
Intervention: Slit-lamp biomicroscopy with Volk 90 D lens
Number of subjects: 25
Study 8795768 — intervention group
Group type: COMPARATOR
Intervention: Heidelberg Retina Tomograph
Number of subjects: 25
Study 1635633 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 0.3 mg/kg
Number of subjects: 48
Study 1635633 — intervention group
Group type: EXPERIMENTAL
Intervention: flunitrazepam 0.03 mg/kg
Number of subjects: 48
Study 1635633 — intervention group
Group type: EXPERIMENTAL
Intervention: promethazine 0.7 mg/kg
Number of subjects: 48
Study 1635633 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 48
Study 1635633 — intervention group
Group type: EXPERIMENTAL
Intervention: haematic levels of DBI
Number of subjects: 48
Study 1635633 — intervention group
Group type: EXPERIMENTAL
Intervention: score scale (STAI, Y, 1‐2)
Number of subjects: 48
Study 6438677 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana cigarette (1.8% THC)
Number of subjects: 28
Study 6438677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 30118363 — intervention group
Group type: EXPERIMENTAL
Intervention: CRoC®
Number of subjects: 49
Study 30118363 — intervention group
Group type: EXPERIMENTAL
Intervention: JETT™
Number of subjects: 49
Study 30118363 — intervention group
Group type: EXPERIMENTAL
Intervention: SJT
Number of subjects: 49
Study 30118363 — intervention group
Group type: EXPERIMENTAL
Intervention: All JTQ devices
Number of subjects: 49
Study 27260271 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture (Vivomixx®)
Number of subjects: 100
Study 27260271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 24767604 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week structured home-based moderate-intensity exercise programme
Number of subjects: 0
Study 24767604 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 0
Study 22698765 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous atrial overdrive pacing (CAOP) ON
Number of subjects: 2343
Study 22698765 — intervention group
Group type: COMPARATOR
Intervention: Continuous atrial overdrive pacing (CAOP) OFF
Number of subjects: 2343
Study 20186392 — intervention group
Group type: EXPERIMENTAL
Intervention: High levator myorrhaphy (HLM)
Number of subjects: 229
Study 20186392 — intervention group
Group type: COMPARATOR
Intervention: Uterosacral ligament suspension (USLS)
Number of subjects: 229
Study 18399862 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (10-week programme of exercise training)
Number of subjects: 30
Study 18399862 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 30
Study 15471618 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone 400 mg/day
Number of subjects: 36
Study 15471618 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone 800 mg/day
Number of subjects: 36
Study 15471618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 15471618 — intervention group
Group type: COMPARATOR
Intervention: Unopposed estrogen
Number of subjects: 36
Study 12089090 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive orthoptic screening at 8, 12, 18, 25, 31, and 37 months
Number of subjects: 3490
Study 12089090 — intervention group
Group type: COMPARATOR
Intervention: Control group (orthoptic screening at 37 months only)
Number of subjects: 3490
Study 10334441 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser lead extraction with the excimer sheath
Number of subjects: 301
Study 10334441 — intervention group
Group type: COMPARATOR
Intervention: Nonlaser lead extraction
Number of subjects: 301
Study 10334441 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser lead extraction
Number of subjects: 301
Study 8951189 — intervention group
Group type: EXPERIMENTAL
Intervention: (+/‐)‐sotalol single doses of 40, 80 and 160 mg
Number of subjects: 0
Study 8951189 — intervention group
Group type: EXPERIMENTAL
Intervention: (+/‐)‐sotalol multiple doses of 80 mg twice daily for 7 consecutive days
Number of subjects: 0
Study 8951189 — intervention group
Group type: EXPERIMENTAL
Intervention: (+/‐)‐sotalol single doses of 80 and 160 mg
Number of subjects: 0
Study 1956099 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 mg transdermal nicotine
Number of subjects: 935
Study 1956099 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 mg transdermal nicotine
Number of subjects: 935
Study 1956099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 935
Study 1956099 — intervention group
Group type: EXPERIMENTAL
Intervention: All transdermal nicotine doses
Number of subjects: 935
Study 30009410 — intervention group
Group type: EXPERIMENTAL
Intervention: POMONA-ESP project methodology
Number of subjects: 0
Study 30009410 — intervention group
Group type: EXPERIMENTAL
Intervention: POMONA-ESP project
Number of subjects: 0
Study 29229440 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline PEP (200 mg single oral dose within 24 hours after sex)
Number of subjects: 232
Study 29229440 — intervention group
Group type: COMPARATOR
Intervention: No PEP
Number of subjects: 232
Study 29229440 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline PEP
Number of subjects: 232
Study 29229440 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline PEP and No PEP
Number of subjects: 232